Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis

BACKGROUND AND AIM: Vedolizumab is a humanized monoclonal antibody that selectively inhibits the migration of gut‐homing memory T cells into the intestinal submucosa by antagonizing the interaction of α(4)β(7) integrin with MAdCAM‐1. Vedolizumab is employed for ulcerative colitis with moderate to se...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Daisuke, Matsuura, Minoru, Ozaki, Ryo, Tokunaga, Sotaro, Minowa, Shintaro, Mitsui, Tatsuya, Miura, Miki, Sakuraba, Akihito, Hayashida, Mari, Miyoshi, Jun, Hisamatsu, Tadakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454470/
https://www.ncbi.nlm.nih.gov/pubmed/34584975
http://dx.doi.org/10.1002/jgh3.12630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454470/
https://www.ncbi.nlm.nih.gov/pubmed/34584975
http://dx.doi.org/10.1002/jgh3.12630

Ejemplares similares